Skip to content

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Point-of-care echocardiography screening for hypertrophic cardiomyopathy using automated deep-learning analysis

Abstract Aims Hypertrophic cardiomyopathy (HCM) remains underdiagnosed due to limited access to expert imaging. We developed and validated a deep-learning (DL)-based echocardiographic model adaptable to point-of-care ultrasound (POCUS) for scalable HCM screening. Methods and results We retrospectively analysed 134 956 expert transthoracic echocardiograms (TTE) from 73 598 patients at Sheba Medical Center (2007–2022). A TTE-trained DL model integrating structural features and temporal motion patterns from parasternal long-axis and apical four-chamber views estimated HCM probability. Performance was evaluated in an independent test cohort and clinical subgroups. External validation used bedside POCUS studies from non-cardiologists with handheld devices. The test cohort included 12 096 patients with 119 confirmed HCM cases (prevalence 0.98%; median age 75 years, 57% male). HCM-positive patients showed increased expert TTE-measured septal (1.67 [1.5, 2.0] vs. 1.01 [0.9, 1.19] cm) and posterior wall thickness (1.1 [1.0, 1.3] vs. 0.9 [0.8, 1.0] cm) (P < 0.001). The model achieved excellent discrimination with an area under the curve of 0.982 (95% CI 0.966–0.993), sensitivity 88.2%, and specificity 97.3%, robust across subgroups. The POCUS cohort (n = 1047, median age 73 years, 55% male) represented multimorbid inpatients with 65 (6.2%) classified as screen-positive by the algorithm. These showed higher expert TTE-measured septal thickness (1.26 [1.07, 1.46] vs. 1.06 [0.9, 1.2] cm; 22% vs. 4% with IVS ≥1.5 cm; P ≤ 0.01). Among 49 (75%) POCUS-flagged positive patients with formal TTE and clinical data, 8 (16%) were confirmed by expert adjudication to have HCM. Specificity is limited by occasional confounding amyloidosis detection (4% of POCUS-flagged patients). Conclusion This DL-based model identifies HCM and demonstrates feasibility for POCUS screening, supporting earlier detection and broader diagnostic access.

N. Karra, Y. Klempfner, Viana Copeland et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.